Theralase Technologies Inc - TLTFF STOCK NEWS

Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company, has announced its proposal to extend the expiry date of 10,000,000 share purchase warrants. The warrants, originally issued on September 22, 2022, as part of a private placement, were set to expire on September 22, 2024. The company now proposes to extend this expiry date to September 22, 2027. These warrants are exercisable at $0.35 per share, and all other terms and conditions will remain unchanged. The extension is subject to final acceptance by the TSX Venture Exchange.

Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF) has announced that its lead drug formulation, Ruvidar, has shown superior effectiveness in destroying the Herpes Simplex Virus 1 (HSV-1) compared to the current standard treatment, Acyclovir. In preclinical studies, Ruvidar demonstrated the ability to inhibit HSV-1 replication by over 10 million-fold, even when administered one day after infection. This breakthrough could lead to the development of novel broad-spectrum antiviral approaches for both prevention and treatment of various viral diseases. The company is now seeking partnerships and licensing opportunities for the commercial development of Ruvidar as a potential topical and oral treatment for herpes simplex.

Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF) has announced that its lead drug formulation, Rutherrin, significantly enhances the efficacy of Cisplatin in chemotherapy-resistant Non-Small Cell Lung Cancer (NSCLC). In a preclinical study using the Lewis Lung Cancer (LLC1) orthotopic model, mice treated with a combination of Cisplatin and Rutherrin showed a significantly higher survival rate (p<0.001) compared to those treated with Cisplatin alone or untreated.

This breakthrough could potentially address the issue of chemotherapy drug resistance in cancer treatment. Theralase plans to commence clinical studies for brain cancer, lung cancer, and various blood-based cancers in 2025, pending sufficient capitalization and completion of Good Laboratory Practice toxicology analysis for Rutherrin.

Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF) has made a significant breakthrough in cancer treatment. Their lead drug formulation, Rutherrin, can now be activated by Metformin, a common diabetes drug, without the need for light or radiation. This discovery allows for precise targeting of cancer cells anywhere in the body, including the brain.

Key findings include:

• Rutherrin combined with Metformin significantly increases Reactive Oxygen Species (ROS) production in Non-Small Cell Lung Cancer (NSCLC) cells
• The combination is even more effective when activated by radiation
• This new method could enable out-patient or in-home cancer treatments
• It potentially reduces treatment costs and burden on patients with mobility

Theralase plans to commence clinical studies for various cancers, pending regulatory approval.

Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF) has released its 2Q2024 financial statements. Key highlights include:

- Total revenue decreased 35% year-over-year

- Gross margin decreased to 33% from 47% in 2023

- Net loss reduced by 6% to $2,400,461

- The company closed three non-brokered private placements, raising approximately $2.7 million

- 72 patients have been enrolled and treated in Study II for BCG-Unresponsive NMIBC CIS

- 63% of treated patients achieved Complete Response (CR)

- 44% of CR patients maintained response for at least 12 months

- The company plans to submit for FDA Break Through Designation in 3Q2024

Theralase aims to complete Study II enrollment by end of 2024 and seeks FDA and Health Canada approval by the end of 2026.

Theralase Technologies, a clinical stage pharmaceutical company, has successfully closed the first tranche of its Non-Brokered Private Placement (NBPP) offering. The company raised $CAN 775,000 by issuing 3,522,729 units at $CAN 0.22 per unit. Each unit includes one common share and one common share purchase warrant, allowing holders to acquire additional shares at $CAN 0.30 each for five years. Funds will support the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study, preclinical research of Rutherrin®, and general corporate purposes. The securities are under a four-month hold and await final acceptance from the TSX Venture Exchange.

Theralase Technologies announced that its lead drug, Rutherrin, has shown promise in repurposing non-cancer drugs for cancer therapy in preclinical research. Rutherrin enhances the efficacy of existing drugs, such as Withaferin A, Amiodarone, and Metformin, in destroying cancer cells. This approach leverages already approved drugs, potentially reducing development costs and timelines. Dr. Arkady Mandel, the Chief Scientific Officer, highlighted the shared molecular pathways between different diseases as a rationale for this repurposing strategy. President Roger DuMoulin-White emphasized the high costs and long timelines of new drug development, underscoring the benefits of repurposing existing drugs for cancer treatment.

Theralase Technologies announced that its lead drug formulation, Rutherrin®, demonstrated a complete response in preclinical studies for Non-Small Cell Lung Cancer (NSCLC). Using a well-established Lewis Lung Cancer (LLC1) model, mice treated with x-ray activated Rutherrin® showed a significant reduction in tumor progression and increased overall survival compared to the control group treated with radiation only. Notably, one mouse achieved a complete response, becoming cancer-free. The company aims to optimize this therapy for higher success rates and expand its cancer treatment targets, which now include bladder, brain, lung, and various blood-based cancers. Pending further research and sufficient funding, Theralase plans to commence clinical studies for these cancers.

Theralase Technologies announced preclinical research revealing that their lead drug, Rutherrin, enhances the efficacy of immunotherapy for cancer treatment. Rutherrin works by killing cancer cells directly and reducing the expression of PD-L1 checkpoint proteins, thus increasing the effectiveness of immunotherapeutic drugs. This combined approach potentially reduces the number of treatments needed and associated side effects. The research was conducted on Non-Muscle Invasive Bladder Cancer (NMIBC) and Glioblastoma Multiforme (GBM) cells, showing significant PD-L1 expression reduction. Additionally, Rutherrin combined with x-ray radiation increased calreticulin expression, an immune system activator, suggesting higher cancer cell destruction rates. Theralase aims to leverage these findings for better cancer treatment outcomes.